23rd week of 2021 patent applcation highlights part 9 |
Patent application number | Title | Published |
20210169791 | FLEECE FOR POUCHED PRODUCT WITH CONTROLLED BASIS WEIGHT | 2021-06-10 |
20210169792 | ORAL COMPOSITIONS AND METHODS OF MANUFACTURE | 2021-06-10 |
20210169793 | STABLE SOLID FINGOLIMOD DOSAGE FORMS | 2021-06-10 |
20210169794 | Surfactant Formulations for Inhalation | 2021-06-10 |
20210169795 | Colloidal Suspensions of Plant Extracts in Aqueous Solutions | 2021-06-10 |
20210169796 | METHODS AND COMPOSITIONS FOR RETINAL DRUG DELIVERY | 2021-06-10 |
20210169797 | Vaginal Hydrogel for Delivery of Therapeutics | 2021-06-10 |
20210169798 | Bendamustine Solution Formulations | 2021-06-10 |
20210169799 | COMPOSITION AND METHOD FOR VANCOMYCIN ORAL LIQUID | 2021-06-10 |
20210169800 | RINSE-OFF COMPOSITIONS AND USES THEREOF FOR DELIVERY OF ACTIVE AGENTS | 2021-06-10 |
20210169801 | CHEMOEMBOLIZATION AGENTS | 2021-06-10 |
20210169802 | EXTRACELLULAR VESICLES DERIVED FROM RECOMBINANT MICROORGANISM INCLUDING POLYNUCLEOTIDE ENCODING TARGET PROTEIN AND USE THEREOF | 2021-06-10 |
20210169803 | METHOD OF LYOPHILIZING LIPOSOMES | 2021-06-10 |
20210169804 | NANOMATERIALS | 2021-06-10 |
20210169805 | EMULSIFIED LIPOSOME COMPOSITION AND PREPARATION PROCESS THEREOF | 2021-06-10 |
20210169806 | AGENTS FOR ORAL COMPOSITION | 2021-06-10 |
20210169807 | PHARMACEUTICAL COMPOSITION COMPRISING AN ATYPICAL ANTIPSYCHOTIC AGENT AND METHOD FOR THE PREPARATION THEREOF | 2021-06-10 |
20210169808 | Tablet Dosage Form For Buccal Absorption Of Active Ingredients | 2021-06-10 |
20210169809 | SOLID DOSAGE FORM PRODUCTION | 2021-06-10 |
20210169811 | CONTROLLED-RELEASE SYSTEM OF ACTIVE PHARMACEUTICAL INGREDIENT AND PREPARATION METHOD THEREFOR | 2021-06-10 |
20210169812 | PURIFIED EXOSOME PRODUCTS, METHOD OF MAKING, AND METHODS OF USING | 2021-06-10 |
20210169813 | FIBRIN PARTICLES AND METHODS OF MAKING THE SAME | 2021-06-10 |
20210169814 | COMPOSITIONS AND METHODS FOR MASKING THE TASTE OF DRUGS | 2021-06-10 |
20210169815 | PROCESS FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS | 2021-06-10 |
20210169816 | WATER SOLUBLE COMPOSITIONS AND METHODS OF MAKING THE SAME | 2021-06-10 |
20210169817 | TUMOUR THERAPEUTIC MONOCLONAL ANTIBODY NANO-CAPSULE AND PREPARATION METHOD AND USE THEREOF | 2021-06-10 |
20210169818 | Transdermal Delivery System | 2021-06-10 |
20210169819 | MICROPARTICLES AND NANOPARTICLES HAVING NEGATIVE SURFACE CHARGES | 2021-06-10 |
20210169820 | CONTROLLED RELEASE CONCENTRATE AND SUSPENSIONS INCLUDING THE SAME | 2021-06-10 |
20210169821 | Method for the manufacture of fibrous dosage forms | 2021-06-10 |
20210169822 | TRANSDERMAL DRUG DELIVERY METHOD AND SYSTEM | 2021-06-10 |
20210169823 | TOPICAL SKIN CARE COMPOSITION AND METHODS FOR TREATING ECZEMA | 2021-06-10 |
20210169824 | USE OF CANNABINOIDS IN THE TREATMENT OF SEIZURES AS ASSOCIATED WITH LENNOX-GASTAUT SYNDROME | 2021-06-10 |
20210169825 | MIXTURE OF RESVERATROL SUPPORTED ON METAL HYDROXIDE AND NON-SUPPORTED PURE RESVERATROL FOR TREATING FEMALE FERTILITY | 2021-06-10 |
20210169826 | HOMOVANILLYL ALCOHOL (HVA), HVA ISOMER, METHODS OF MAKING COMPOSITIONS COMPRISING SUCH COMPOUNDS, AND METHODS USING SUCH COMPOUNDS | 2021-06-10 |
20210169827 | AGENTS FOR REVERSING TOXIC PROTEINOPATHIES | 2021-06-10 |
20210169828 | Adelmidrol For Use In Diseases Characterized By Insufficient Agonism Of PPAR-GAMMA Receptor | 2021-06-10 |
20210169829 | METHODS AND COMPOSITIONS TO MODULATE THE GUT MICROBIOTA AND TO MANAGE WEIGHT | 2021-06-10 |
20210169830 | REAGENTS, COMPOSITIONS AND METHODS FOR IMPROVING VIABILITY AND FUNCTION OF CELLS, TISSUES AND ORGANS | 2021-06-10 |
20210169831 | KETONE BODY ESTERS OF S-BETA-HYDROXYBUTYRATE AND/OR S-1,3-BUTANEDIOL FOR MODIFYING METABOLIC FUNCTION | 2021-06-10 |
20210169832 | METHOD OF TREATING TEMPOROMANDIBULAR JOINT DISORDERS | 2021-06-10 |
20210169833 | METHODS AND COMPOSITIONS FOR TREATING EDEMA REFRACTORY TO ORAL DIURETICS | 2021-06-10 |
20210169834 | AMYLOID FIBER FORMATION LIMITER OR INHIBITOR | 2021-06-10 |
20210169835 | METHODS OF TREATMENT USING AN mTORC1 MODULATOR | 2021-06-10 |
20210169836 | Oral Care Product and Methods of Use and Manufacture Thereof | 2021-06-10 |
20210169837 | COMPOSITION FOR REDUCING NEW-ONSET DIABETES | 2021-06-10 |
20210169838 | Novel class of compounds for the treatment of cardiovascular disease. | 2021-06-10 |
20210169839 | PEDIATRIC IMMEDIATE-RELEASE FORMULATION OF THE POTASSIUM CHANNEL OPENER EZOGABINE | 2021-06-10 |
20210169840 | COMPOSITION AND METHOD OF AN IRON SUPPLEMENT | 2021-06-10 |
20210169841 | METHOD FOR TREATMENT OF ROSACEA IN PATIENTS AGED 65 YEARS AND OLDER | 2021-06-10 |
20210169842 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | 2021-06-10 |
20210169843 | NOVEL ANTITUMORAL USE OF CABAZITAXEL | 2021-06-10 |
20210169844 | COMPOSITIONS AND METHODS FOR TREATING EPILEPSY, SEIZURES AND OTHER CONDITIONS | 2021-06-10 |
20210169845 | NOVEL DOSAGE FORMS OF ROFECOXIB AND RELATED METHODS | 2021-06-10 |
20210169846 | SYNTHESIS OF NOVEL XYLOSE FREE OCCIDIOFUNGIN ANALOGUES AND METHODS OF USING THEM | 2021-06-10 |
20210169847 | METHODS OF TREATING CHEMOTHERAPY OR RADIOTHERAPY INDUCED NEUTROPENIA | 2021-06-10 |
20210169848 | USE OF NEUROKININ-1 ANTAGONISTS TO TREAT PRURITUS | 2021-06-10 |
20210169849 | LIQUID PHARMACEUTICAL COMPOSITIONS | 2021-06-10 |
20210169850 | INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | 2021-06-10 |
20210169851 | USE OF MARIZOMIB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS | 2021-06-10 |
20210169852 | PROTEIN RECOGNIZING DRUG MOIETY OF ANTIBODY-DRUG CONJUGATE | 2021-06-10 |
20210169853 | CORROLES FOR TREATING POXVIRUS INFECTION | 2021-06-10 |
20210169854 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation | 2021-06-10 |
20210169855 | STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES | 2021-06-10 |
20210169856 | FORMULATIONS COMPRISING DOPAMINE-B-HYDROXYLASE INHIBITORS AND METHODS FOR THEIR PREPARATION | 2021-06-10 |
20210169857 | THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN OR INSULIN ANALOGS | 2021-06-10 |
20210169858 | THERAPEUTIC USES OF GLUCOKINASE ACTIVATORS IN COMBINATION WITH INSULIN OR INSULIN ANALOGS | 2021-06-10 |
20210169859 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | 2021-06-10 |
20210169860 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS | 2021-06-10 |
20210169861 | R-FADROZOLE FOR USE IN THE TREATMENT OF ALDOSTONERISM | 2021-06-10 |
20210169862 | Methods for the Administration of Certain VMAT2 Inhibitors | 2021-06-10 |
20210169863 | DECREASING EXPRESSION LEVEL OF PROTEASOME SUBUNIT GENES BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | 2021-06-10 |
20210169864 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | 2021-06-10 |
20210169865 | COMBINATION OF BCL-2 INHIBITOR AND MEK INHIBITOR FOR THE TREATMENT OF CANCER | 2021-06-10 |
20210169866 | Pharmaceutical Composition | 2021-06-10 |
20210169867 | MOIST ORAL COMPOSITIONS | 2021-06-10 |
20210169868 | ORAL COMPOSITIONS WITH REDUCED WATER CONTENT | 2021-06-10 |
20210169869 | Compound for Use Against Pathogenic Neisseria and Haemophilus Species and Moraxella Catarrhalis | 2021-06-10 |
20210169870 | USES OF FERMENTATION PRODUCT OF LOTUS LEAF-HAWTHORN EXTRACT AND ITS ACTIVE INGREDIENT IN INHIBITING THE FORMATION OF FAT | 2021-06-10 |
20210169871 | PHARMACEUTICAL COMPOSITIONS WITH REDUCED TERT-BUTANOL LEVELS | 2021-06-10 |
20210169872 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | 2021-06-10 |
20210169873 | Storage-stable ready-to-use injectable formulations of Trabectedin | 2021-06-10 |
20210169874 | ANTICOAGULANT REVERSAL AGENTS | 2021-06-10 |
20210169875 | TREATING CARDIOVASCULAR DISEASE BY SELECTIVELY ELIMINATING SENESCENT CELLS | 2021-06-10 |
20210169876 | TREATING LIVER DISEASE BY SELECTIVELY ELIMINATING SENESCENT CELLS | 2021-06-10 |
20210169877 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-(3,5-DIMETHOXYPHENYL)-N'-(1-METHYLETHYL)-N-[3-(1-METHYL-1H-PYRAZOL-4-YL- )QUINOXALIN-6-YL]ETHANE-1,2-DIAMINE | 2021-06-10 |
20210169878 | COMBINATION OF ANTI-CD20 ANTIBODY, P13 KINASE-DELTA SELECTIVE INHIBITOR, AND BTK INHIBITOR TO TREAT B-CELL PROLIFERATIVE DISORDERS | 2021-06-10 |
20210169879 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | 2021-06-10 |
20210169880 | CONTROL AND MODULATION OF THE FUNCTION OF GENE-MODIFIED CHIMERIC ANTIGEN RECEPTOR T CELLS WITH DASATINIB AND OTHER TYROSINE KINASE INHIBITORS | 2021-06-10 |
20210169881 | COMBINATION OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE WITH AN SGLT-2 INHIBITOR FOR THE TREATMENT OF ENDOTHELIN RELATED DISEASES | 2021-06-10 |
20210169882 | PHARMACEUTICAL COMPOSITION FOR PROTECTING OR MITIGATING RADIATION DAMAGE, AND FOR PREVENTING OR TREATING PULMONARY FIBROSIS | 2021-06-10 |
20210169883 | METHOD OF TREATING AGGRESSION WITH OREXIN RECEPTOR ANTAGONISTS | 2021-06-10 |
20210169884 | ALPHA POLYGLUTAMATED RALTITREXED AND USES THEREOF | 2021-06-10 |
20210169885 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | 2021-06-10 |
20210169886 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | 2021-06-10 |
20210169887 | ALPHA POLYGLUTAMATED METHOTREXATE AND USES THEREOF | 2021-06-10 |
20210169888 | FORMULATIONS/COMPOSITIONS COMPRISING A BTK INHIBITOR | 2021-06-10 |
20210169889 | ORAL PRODUCTS | 2021-06-10 |
20210169890 | ORAL COMPOSITION WITH POLYMERIC COMPONENT | 2021-06-10 |
20210169891 | COMPOSITION AND METHOD TO ENHANCE PERFORMANCE FOR ELECTRONIC VIDEO GAME PLAY | 2021-06-10 |